Santen Pharmaceutical, Oakwood Laboratories Conclude Licensing Agreement for Microsphere Formulation Development.Tokyo, Japan, Mar 30, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Santen Pharmaceutical has signed a licensing agreement with Oakwood of Ohio for the development of the microsphere formulation of a steroid (DE- de- word element [L.], down; from; sometimes negative or privative, and often intensive. de- pref. 1. Do or make the opposite of; reverse: decomposition. 2. 102) for diabetic macular edema (DME (Distributed Management Environment) A network monitoring and control protocol defined by the Open Software Foundation (now The Open Group). DME was not widely used. DME - Distributed Management Environment ), a kind of diabetic complication that may induce visual impairment and blindness. Under the agreement terms, the two companies will strive to develop a drug delivery system (DDS (1) (Digital Data Storage) See DAT. (2) (Data Dictionary System) See QuickBuild and OpenDDS. (3) (Dataphone Digital S ) based on Oakwood's CHRONIJECT microsphere technology. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion